Skip to main content
. 2020 Nov 6;8(2):e001355. doi: 10.1136/jitc-2020-001355

Figure 6.

Figure 6

Proof-in-concept that inhaled IL-15 drives peripheral NK and CD8+ T cell activation and TIGIT upregulation in dogs with metastatic osteosarcoma. (A) Schema for our first-in-dog clinical trial of inhaled IL-15 in dogs with naturally occurring metastatic osteosarcoma. (B) Representative flow cytometry showing peripheral blood CD45+, lymphocytes, CD3, CD3NKp46+ NK, and CD3+CD8+ T cell populations. (C–D) Inhaled IL-15 stimulates peripheral cytotoxic lymphocytes in vivo leading to upregulation of granzyme B and Ki67 by flow cytometry analysis. (E–F) Fold change in granzyme B expression significantly increased on NK cells (p=0.01) and fold change in Ki67 expression significantly increased on T cells (p=0.03). (G) RNA sequencing analysis of CD5-depleted NK cells from three dogs on-trial showing TIGIT upregulation in 2/3 patients. Mean±SEM. P values determined using paired Student’s t-test. Fold change comparison using Pre Tx value of 1. IL-15, interleukin 15; NK, natural killer; On Tx, on treatment; Pre Tx, pretreatment.